AMENDMENT #1 TO THAT CERTAIN 18% SENIOR SECURED PROMISSORY NOTE DUE JULY 1, 2018
Exhibit 4.25
AMENDMENT #1
TO THAT CERTAIN
18% SENIOR SECURED PROMISSORY NOTE DUE JULY 1, 2018
This Amendment #1 (this “Amendment”), dated as of June 3, 2018, is by and between Adial Pharmaceuticals, Inc., a Delaware corporation, (the “Company”) and the holders (“Holders”) of those certain 18% Senior Secured Promissory Note Due July 1, 2018 (the “Notes”) issued as a series pursuant to Securities Purchase Agreements dated February 22, 2018 and March 19, 2018. Together, the “Parties” and each a “Party”.
WHEREAS, the Notes provide that the Notes will be senior to all other debts of the Company;
WHEREAS, the original principal balance of the Notes was $510,000;
NOW, THEREFORE, the Parties agree as follows:
1. | The Maturity Date (as defined in the Notes) is hereby amended to be August 1, 2018. |
2. | The second paragraph of the Notes is replaced in its entirety with the following: |
“The Maturity Date is subject to extensions as follows. If an Event of Default (as defined below) has not then occurred and the Company is otherwise in compliance with the terms of this 18% Senior Secured Promissory Note (this “Note”) and the other Transaction Documents (as defined below), the Company may: (i) elect to extend the Maturity Date to the 6 month anniversary of the Issue Date (the “First Extended Maturity Date”) upon payment to Holder of an extension fee equal to 99.4% of the principal amount of this Note; and (ii) elect to extend the Maturity Date from the First Extended Maturity Date to the 7 month anniversary of the Issue Date upon payment to Holder of an extension fee equal to 46.3% of the principal amount of this Note. Each such extension fee may, at the election of the Holder, be paid in cash to Holder at the time of such extension or be added to the principal amount of this Note.”
3. | The Notes are hereby amended to allow the issuance of the New Note in a ranking/seniority pari passu with the Notes. |
4. | All other terms of the Notes remain unchanged. |
[Signature page follows]
For ADIAL PHARMACEUTICALS, INC. | ||||
By: | /s/ Xxxxxx Xxxxxxx | |||
Name: | Xxxxxx Xxxxxxx |
|||
Title: | Chief Operating Officer and Chief Financial Officer |
For HOLDERS: | ||||
For Xxxxxxx X. Xxxxxxx | For Ivy Cottage Group LLC | |||
Original Principal: $46,000.00 | Original Principal: $25,000.00 | |||
/s/ Xxxxxxx X. Xxxxxxx | /s/ Xxxxx X. Xxxxxx, Xx. | |||
Xxxxxxx X. Xxxxxxx | Xxxxx X. Xxxxxx, Xx. | |||
For Xxxxxxx X. Xxxxxxx | For Xxxx Xxx Xxxxxxx, Xx. | |||
Original Principal: $5,000.00 | Original Principal: $10,000.00 | |||
/s/ Xxxxxxx X. Xxxxxxx | ||||
Bankole A. Xxxxxxx | Xxxx Xxx Xxxxxxx, Xx. | |||
For Medico-Trans Company | For MVA 151 Investors LLC | |||
Original Principal: $17,000.00 | Original Principal: $150,000.00 | |||
/s/ Xxxxx Xxxxxxxx | ||||
Carolina X. Xxxxxxx | Xxxxx Xxxxxxxx | |||
Director | Managing Member | |||
For Xxxxx Xxxxxxxx | For Xxxxx Ventures LLC | |||
Original Principal: $112,000.00 | Original Principal: $115,000.00 | |||
/s/ Xxxxx Xxxxxxxx | /s/ Xxxxx X. Xxxxxx, Xx. | |||
Xxxxx Xxxxxxxx | Xxxxx X. Xxxxxx, Xx. | |||
For Xxxxx Xxxxxxx |
||||
Original Principal: $30,000.00 |
||||
/s/ Xxxxx Xxxxxxx | ||||
Xxxxx Xxxxxxx |